Intravenous zoledronate (Reclast) administered once every 5 years reduced the incidence of morphometric vertebral fractures in early postmenopausal women, a randomized trial showed. Over 10 years of ...

Following an infusion of zoledronate acid in low-risk postmenopausal women, fracture risk reduction emerged only 5-10 years later in a placebo-controlled trial. By year 10, those who received a single ...

The researchers found that 6.3, 6.6, and 11.1% of the zoledronate-zoledronate, zoledronate-placebo, and placebo-placebo groups, respectively, had a new morphometric fracture at follow-up. HealthDay ...

Please provide your email address to receive an email when new articles are posted on . Discontinuation of denosumab is associated with a rapid return to pretreatment BMD levels and an increased risk ...

Women in early menopause treated with zoledronate in just two infusions, 5 years apart, show a significantly reduced risk of sustaining a vertebral fracture and better maintenance of bone mineral ...

Please provide your email address to receive an email when new articles are posted on . The effects of two annual 4-mg doses of intravenous zoledronate in HIV-infected men linger for at least 5 years ...

Zoledronate prevents fractures in older women when administered every 12 to 18 months, but its effects on bone density and bone turnover persist beyond 5 years. Whether infrequent zoledronate ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

Credit: Shutterstock. The researchers found that a fragility fracture occurred in 190 women in the placebo group and 122 women in the zoledronate group (hazard ratio [HR] with zoledronate, 0.63).

MESSINA, Italy — Although the bisphosphonate zoledronic acid, or zoledronate (Aclasta, Reclast, Novartis), stops bone loss in patients with osteoporosis, it also ups levels of the protein biomarker ...

Editor's note: This story was updated on Oct. 23, to add conflict-of-interest disclosures for the lead author of the research study. A large study has produced strong evidence that a drug commonly ...